Tiziana Reports Promising Data Showing Nasal Anti-CD3 May Improve Age-Related Cognitive Decline [TheStreet.com]
Tiziana Life Sciences Ltd - Common Shares (TLSA)
Company Research
Source: TheStreet.com
Tiziana Life Sciences (Nasdaq: TLSA) has released new preclinical data demonstrating that its intranasal anti-CD3 therapy , foralumab, may help reverse key aspects of brain aging and improve cognition. The findings highlight the drug's potential to target neuroinflammation—one of the primary drivers of age-related cognitive decline. First, the study showed that nasal anti-CD3 significantly reduced microglial activation, a key contributor to chronic neuroinflammation in the aging brain. By dampening this inflammatory response, the therapy may lower the biological stress that accelerates cognitive decline. At the same time, researchers observed that the treatment enhanced neurogenesis in the hippocampus, the brain region responsible for learning and memory. In addition, the therapy reduced cellular senescence by downregulating inflammatory markers and age-associated genes. Together, these effects suggest a dual mechanism: reducing damage while promoting repair. According to Dr. H
Show less
Read more
Impact Snapshot
Event Time:
TLSA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TLSA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TLSA alerts
High impacting Tiziana Life Sciences Ltd - Common Shares news events
Weekly update
A roundup of the hottest topics
TLSA
News
- Tiziana says intranasal drug shows potential to ease Long COVID “brain fog” [Yahoo! Finance]Yahoo! Finance
- Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive FunctionGlobeNewswire
- Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson CongressGlobeNewswire
- Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with AgingGlobeNewswire
- Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRAGlobeNewswire
TLSA
Sec Filings
- 4/16/26 - Form 6-K
- 4/14/26 - Form 6-K
- 4/1/26 - Form 6-K
- TLSA's page on the SEC website